Human HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein

Name: Human HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein
Brand: 普维拓生物
SKU: KRASG12A-HP002

货号KRASG12A-HP002

HumanHEK293分子名 · MHC理论分子量 · 258 kDa

产品简介

Recombinant Human HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus, tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAAGVGK peptide (accession: AAV53343.1(HLA-A*11:01) & P61769(B2M) &VVVGAAGVGK).

产品详情

分子别名: MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
蛋白长度: Gly25-Thr305
表达系统: HEK293
理论分子量: The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reduced (N) condition based on Bis-Tris PAGE result.
纯度: > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
内毒素: Less than 1 EU per μg by the LAL method.
缓冲液 / 制剂: Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
状态: 冻干粉
储存条件: -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
复溶建议: Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.

数据展示

Bis-Tris PAGE Data — Human HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer on Bis-Tris PAGE under Non reduced (N) condition. The purity is greater than 95%.

SEC-HPLC Data — The purity of Human HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer is greater than 95% as determined by SEC-HPLC.

背景介绍

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

文献引用

1.(1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.

加载中…

Human HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein

货号KRASG12A-HP002

HumanHEK293分子名 · MHC理论分子量 · 258 kDa

Human HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein

产品简介

产品详情

数据展示

Bis-Tris PAGE

Bis-Tris PAGE Data

SEC-HPLC

SEC-HPLC Data

背景介绍

文献引用

Human HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Tetramer Protein

产品简介

产品详情

数据展示

Bis-Tris PAGE

Bis-Tris PAGE Data

SEC-HPLC

SEC-HPLC Data

背景介绍

文献引用